{
    "medicine_id": "725cecfafe875f5dd7aa9275f6fd5a3aff03cf65",
    "platform_id": "DB06436",
    "metadata": {
        "name": "Bles 50 mg 1 2mL Suspension",
        "composition": "50 mg 1 2mL Semaxanib",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in colorectal cancer and lung cancer",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Semaxanib"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Semaxanib"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Semaxanib"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Semaxanib"
                    },
                    {
                        "drugbank-id": "DB00282",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Pamidronic acid"
                    },
                    {
                        "drugbank-id": "DB00399",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Zoledronic acid"
                    },
                    {
                        "drugbank-id": "DB00630",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00710",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00720",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Clodronic acid"
                    },
                    {
                        "drugbank-id": "DB00884",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Risedronic acid"
                    },
                    {
                        "drugbank-id": "DB01077",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Etidronic acid"
                    },
                    {
                        "drugbank-id": "DB01133",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Tiludronic acid"
                    },
                    {
                        "drugbank-id": "DB06255",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Semaxanib is combined with Incadronic acid"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}